Skip to main content

Table 1 Clinico-pathological characteristics of breast cancer patients.

From: A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer

Variable

Categorisation

Control

Celecoxib

  

Number = 15

Number = 22

Mean age ± SD (years)a

57 ± 12

51 ± 12

Histological tumour typeb

 

Invasive ductal carcinoma

13 (87%)

19 (86%)

 

Invasive lobular carcinoma

2 (13%)

3 (14%)

Tumour sizec

 

pT1

10 (67%)

8 (36%)

 

pT2

5 (33%)

13 (59%)

 

pT3

0 (0%)

1 (5%)

Lymph node statusc

 

Negative (pN0)

11 (73%)

10 (45%)

 

Positive (pN1-3)

4 (27%)

12 (55%)

Tumour graded

 

G1

5 (33%)

1 (5%)

 

G2

4 (27%)

7 (32%)

 

G3

6 (40%)

14 (63%)

Oestrogen receptor statuse

 

ER positive

11 (73%)

19 (86%)

 

ER negative

4 (27%)

3 (14%)

Progesterone receptor statuse

 

PgR positive

10 (67%)

17 (77%)

 

PgR negative

5 (33%)

5 (23%)

HER2 statusf

 

HER2 positive

3 (20%)

3 (14%)

 

HER2 negative

12 (80%)

18 (82%)

 

Unknown

0 (0%)

1 (5%)

  1. aAt time of diagnosis; baccording to Tavassoli and Devilee [20]; caccording to Sobin and Wittekind [21]; daccording to Elston and Ellis [22]; epositivity defined as > 10% positive cells as analysed by immunohistochemistry [60]; fpositivity defined by immunohistochemistry (score 3+) or by dual-color FISH. Percentages may not sum-up to 100 due to rounding. FISH, fluorescence in situ hybridisation.